AESI Case Definition Companion Guide: Acute Myelitis
This post contains the Companion Guide for Acute Myelitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They contain resources and tools specific…
Addendum to Priority List of Adverse Events of Special Interest: COVID-19
The Coalition for Epidemic Preparedness Innovations (CEPI) has contracted with the Brighton Collaboration, through the Task Force for Global Health (TFGH), to harmonize the safety assessment of CEPI-funded vaccines via its Safety Platform for…
Vaccine-associated Enhanced Disease: Case Definition and Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data
This is a Brighton Collaboration case definition of the term “Vaccine-associated Enhanced Disease” (VAED) to be utilized in the evaluation of adverse events following immunization. The case definition was developed…
Repositories of Publications and Safety Profiles from COVID-19 Vaccine Clinical Trials
To find updated repositories of publications and safety profiles from COVID-19 vaccine clinical trials, please visit one or both of the following external sites: The COVID-19 vaccine tracker from the…
Brighton Collaboration Added to Vaccine Safety Net
Brighton Collaboration (BC) has been added to the Vaccine Safety Net (VSN). VSN is a global network of websites, established by the World Health Organization (WHO), that provides reliable information…
Webinar on Assessment of Vaccine Mediated Enhanced Disease in Epidemiologic Studies Monitoring COVID-19 Vaccines
Vaccine monitoring Collaboration for Europe (VAC4EU) and the Brighton Collaboration's Safety Platform for Emergency vACcines (SPEAC) project jointly held a scientific webinar on how to assess Vaccine Mediated Enhanced Disease…
Webinar on Tools for COVID-19 Vaccine Safety Assessment
Brighton Collaboration's Webinar on Tools for COVID-19 Vaccine Safety Assessment was held on Thursday, August 27th at 11 AM - 12:30 PM EDT | 5 PM - 6:30 PM CEST.For…
Standardized Template for Collection of Key Information for Benefit-Risk Assessment of Inactivated Viral Vaccines
Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC) Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as part of the Safety Platform for Emergency…
New Working Groups to be Established to Develop Guidance on Digital Apps for Vaccine Safety Data Collection
Digital apps have much potential for improving the quality of safety data collected during both pre and post-introduction of new vaccines, including SARS-COV-2 candidate vaccines. Brighton Collaboration (BC) is forming two inter-related…
New Brighton Collaboration Working Groups to be Established to Develop Case Definitions for Four COVID-19 Adverse Events of Special Interest (AESI)
The Coalition for Epidemic Preparedness Innovation (CEPI) has partnered with the Brighton Collaboration to support the safety assessment of its candidate vaccines, including SARS-COV-2. Four AESI have been targeted for case…
- 1
- 2